ArticlePloS one2025
Non-adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence.Neuropsychopharmacology reports · 2026Review
- Antipsychotic prescribing patterns and determinants in first-episode psychosis: a 2019-2024 cross-sectional study from Zambia.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSchizophrenia is a chronic and profound mental disorder. Non-adherence to prescribed medication regimens is a major concern in the treatment of schizophrenia. This study aimed to investigate the prevalence, factors, and reasons contributing to non-adherence among Ethiopian patients with schizophrenia who are receiving second-generation antipsychotics (SGAs).
methodsA hospital-based cross-sectional study was done at Amanuel Mental Specialized Hospital (AMSH) from 03/10/2022 to 31/8/2023. Data were collected using the drug attitude inventory-10 (DAI-10) tool. Analysis was conducted using Statistical Package for Social Sciences (SPSS) version 25. Univariate and multivariate binary logistic regression analyses were conducted.
resultsMost participants were male, (90.0%), and aged 26-40 years, (53.5%). Mean doses for risperidone and olanzapine prescribed were 4.9mg (±2.4) and 13.5mg (±5.0), respectively. Close to 40% of patients were khat (Catha edulis) users. The mean Positive and Negative Syndrome Scale (PANSS) total score was 71.1 ± 35.9 and the Clinical Global Impression-Severity (CGI-S) score was 3.42 ± 1.21. Around 31.4% of participants were non-adherent. Forgetfulness (31.73%) and stigma (27.31%) were the primary reasons cited for non-adherence. The multivariate binary logistic regression analysis revealed a significant association between non-adherence and several key factors. Patients with a PANS score equal to or greater than 71 (95% CI: 1.04, 3.80; p = 0.02), Patients categorized as having a moderate to markedly severe illness (95% CI: 1.1, 3.1; p = 0.024), duration of follow-up (DUP) (6-10) years (95% CI: 1.4, 129; p = 0.02), and age (26-40) years (95% CI: 0.3, 0.9; p = 0.04) were found to be statistically significant predictors of non-adherence.
conclusionThe investigators recommended that counseling of the patients to highlight the importance of adherence, instituting regular and comprehensive symptom monitoring, tailoring interventions to address reasons for non-adherence, promoting early intervention and treatment initiation to reduce the DUP, and customizing interventions based on age-specific needs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.